- Home
- ADUR vs ATOS Comparison
ADUR vs ATOS Comparison
Compare ADUR & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADUR
- ATOS
- Stock Information
- Founded
- ADUR 2011
- ATOS 2009
- Country
- ADUR Canada
- ATOS United States
- Employees
- ADUR N/A
- ATOS N/A
- Industry
- ADUR
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- ADUR
- ATOS Health Care
- Exchange
- ADUR NYSE
- ATOS Nasdaq
- Market Cap
- ADUR 154.9M
- ATOS 174.8M
- IPO Year
- ADUR N/A
- ATOS 2012
- Fundamental
- Price
- ADUR $5.50
- ATOS $1.22
- Analyst Decision
- ADUR
- ATOS Strong Buy
- Analyst Count
- ADUR 0
- ATOS 3
- Target Price
- ADUR N/A
- ATOS $6.75
- AVG Volume (30 Days)
- ADUR 126.5K
- ATOS 792.8K
- Earning Date
- ADUR 01-01-0001
- ATOS 11-12-2024
- Dividend Yield
- ADUR N/A
- ATOS N/A
- EPS Growth
- ADUR N/A
- ATOS N/A
- EPS
- ADUR N/A
- ATOS N/A
- Revenue
- ADUR $247,485.00
- ATOS N/A
- Revenue This Year
- ADUR N/A
- ATOS N/A
- Revenue Next Year
- ADUR N/A
- ATOS N/A
- P/E Ratio
- ADUR N/A
- ATOS N/A
- Revenue Growth
- ADUR 98.59
- ATOS N/A
- 52 Week Low
- ADUR $1.34
- ATOS $0.70
- 52 Week High
- ADUR $7.00
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- ADUR N/A
- ATOS 35.57
- Support Level
- ADUR N/A
- ATOS $1.26
- Resistance Level
- ADUR N/A
- ATOS $1.66
- Average True Range (ATR)
- ADUR 0.00
- ATOS 0.09
- MACD
- ADUR 0.00
- ATOS -0.03
- Stochastic Oscillator
- ADUR 0.00
- ATOS 10.20
About ADUR ADURO CLEAN TECHNOLOGIES INC
Aduro Clean Technologies Inc is a developer of patented water-based technologies to chemically recycle plastics and transform heavy crude and renewable oils into feedstocks and higher-value fuels. The company's technology activates unique properties of water in a chemistry platform that operates at relatively low temperatures and costs.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.